RCUSArcus Biosciences, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+26.9% YoY

Gross Profit

$30M90.9% margin

Operating Income

-$114M-345.5% margin

Net Income

-$98M-297.0% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

+26.9%

Cash Flow

Operating Cash Flow

-$120M

Free Cash Flow

-$121M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$508M

Stockholders' Equity

$631M

Cash & Equivalents

$222M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$26M	+26.9%
Gross Profit	$30M	$26M	+15.4%
Operating Income	-$114M	-$103M	-10.7%
Net Income	-$98M	-$94M	-4.3%

RCUS Q4 2025 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena